Belite Bio, Inc
BLTE
Rank in Stocks
#3078
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Share Price
$146.18
Market Cap
$5.89B
Change (1 day)
2.38%
Change (1 year)
66.66%
Country
US
Trade Belite Bio, Inc (BLTE)
Category
Healthcare
Stock split history for Belite Bio, Inc (BLTE)
Belite Bio, Inc stock (symbol: BLTE) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 19, 2026.
One BLTE share bought prior to Oct 19, 2026 would equal to 0 BLTE shares today.
The most recent stock split occurred on Oct 19, 2026.
One BLTE share bought prior to Oct 19, 2026 would equal to 0 BLTE shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
